L'hémochromatose HFE due à la mutation C282Y entraine une surcharge en fer progressive. La surmortalité se produit après 50ans. La saignée répétée est un traitement efficace de peu d'effets secondaires. Justifier le dépistage est discuté depuis 60ans et dépend de l'efficacité du traitement et de la pénétrance en fonction d'enjeux économiques et sociaux. Ce travail apporte des éléments tirés de la cohorte LOGIFER depuis 25ans au CHU de Rennes, composée de 1835 homozygotes consultants du CHU, issus d'enquêtes ciblées, référés au CNR ou parents. Les motifs de recrutement, le sexe et l'âge ont évolué. 2/3 des patients sont des probants dont la moitié issus de dépistage, d'une meilleure représentativité. Le sexe-ratio est de 1.2. Ils sont caractérisés par la mélanodermie et les hépatopathies. Les atteintes articulaires sont peu spécifiques. Les mesures classiques de la surcharge sont univoques, très hétérogène selon les individus, elle augmente au moins jusque 60ans. Les femmes stockent le fer lentement jusqu'à la ménopause. L'alcool et le syndrome métabolique aggravent la surcharge. L'alcool accélère le dépistage clinique. Le syndrome métabolique crée une surcharge modérée, les arthropathies associées concernent d'autres articulations. Environ 20% des troubles au diagnostic contribuent à la pénétrance. L'Iron removal index repose sur la quantité de fer ôté pour entretenir le statut martial. Il a 2 usages probablement valables pour d'autres hémochromatoses. Mesurer la vitesse d'absorption du fer propre à un patient, complétant le phénotype et donnant une vue dynamique du risque de surcharge au contraire des critères classiques. Fournir un cadre de pilotage des saignées. Le rythme de traitement est personnalisable et prévisible au diagnostic (âge, sexe, fibrose, objectif de ferritine, poids). Corollairement, l'évolution du statut martial sous saignées implique des explorations complémentaires. Les patients génotypés suivis 8.5ans pendant le traitement ont une mortalité de 5%. A 54ans, il n'y a pas de surmortalité après ajustement sur le sexe, le lieu et l'année de naissance. Il y a une mortalité hépatique significative surtout des cancers primaires (ICM=18). Ils décèdent dans les 5ans du diagnostic. Elle est compensée par une sous-mortalité ultérieure cardiaque ou par d'autres cancers. La durée de vie baisse pour les patients anciennement recrutés en partie due au diagnostic tardif et aux traitements adjuvants moins efficaces. L'âge au décès va de 64 à 68ans. L'effet des saignées n'est pas quantifiable mais milite pour le traitement précoce. Le prédicteur de cirrhose de Guyader s'adapte à la prédiction des fibroses (indice de Youden similaire). L'analyse discriminante prédit les stades METAVIR avec un contrôle de fiabilité. Ces équations sont les meilleurs prédicteurs parmi les index proposés par la littérature. Le développement des résultats passe par la mise en place d'études longitudinales entre 65 et 80ans et l'étude des pathologies non létales. / Hemochromatosis due to the HFE mutation C282Y causes a progressive iron overload. The mortality occurs after 50 years. Repeated bleeding is an effective treatment with marginal side effects. The rationale for screening, debated for 60 years, depends on the penetrance and the effectiveness of treatment relatively to economic and social issues. This work provides evidence from cohort LOGIFER, 25 years old at the CHU of Rennes, composed of 1835 homozygous: consultants from CHU, from targeted surveys, referred to the NRC or related. The reasons for recruitment, gender and age have changed. 2/3 of patients are probants, half of them coming from screening, providing better representativity. The sex ratio was 1.2. They are characterized by skin pigmentation and liver disease. Joint involvement are nonspecific. Traditional measures of overload are unequivocal , highly heterogeneous among individuals and increases until at least 60 years. Women store iron slowly until menopause. Alcohol and metabolic syndrome worse overload. Alcohol accelerates the clinical discover. Metabolic syndrome creates a moderate overload, associated arthropathies involve other joints. Approximately 20% of clinical signs at diagnosis contribute to the penetrance. The Iron removal index is based on the amount of iron removed to maintain iron status . It has two usages probably valid for other hemochromatosis. Measuring the rate of absorption of iron for a specific patient, supplementing the phenotype and giving a dynamic view of the risk of overload unlike conventional criteria. Providing a framework for controlling the bleeding pattern. The processing rate is customizable and predictable at diagnosis (age, sex, fibrosis, ferritin target, weight). Con,sequently, changes in iron status during maintaining treatment involves complementary explorations. Genotyped patients monitored for 8.5 years during treatment have a mortality rate of 5%. At 54 years, there is no excess mortality after adjustment for sex, place and year of birth. There is a significant hepatic mortality especially primary liver cancers (ICM=18). They die within 5 years of diagnosis. It is offset by a subsequent under mortality from heart diseases or other cancers. Life expectancy down for patients initially enrolled in part due to delayed diagnosis and less effective adjuvant treatments. The age at death is 64 to 68 years. The effect of phelbotomies is not quantifiable but advocates for early treatment. The Guyader's predictor of cirrhosis adapts to the prediction of fibrosis (similar Youden index). Discriminant analysis predicts METAVIR stages with the benefit of a reliability check. These equations are the best predictors among candidates proposed by the literature. Development goes through the implementation of longitudinal studies between 65 and 80 years and the study of non-lethal forms.

La présentation antigénique par le complexe majeur d’histocompatibilité (MHC) I est un processus ubiquitaire permettant la présentation de protéines endogènes qui reflètent l'état de la cellule à la surface cellulaire aux lymphocytes T CD8+ dans le contexte de la surveillance et la réponse immunitaires. Ainsi, l'expression des molécules du MHC I classiques est induite en réponse aux stimuli inflammatoires afin de favoriser la reconnaissance immunitaire et l'élimination des pathogènes. HFE est une molécule du MHC Ib non-classique qui sert de régulateur négatif de l'absorption du fer. HFE est associé au développement de l'hémochromatose héréditaire (HH), maladie associée au métabolisme du fer mais souvent accompagnée de défauts immunitaires. Ainsi, nous avons en premier lieu étudié l'impact de HFE sur la présentation antigénique par MHC I, afin d'expliquer en partie les défauts immunitaires liés à l'HH associée à HFEC282Y. Puis, compte tenu de l'impact de l'inflammation sur l'expression des molécules du MHC I classiques, nous avons étudié la régulation de l'expression de HFE en réponse aux stimuli inflammatoires induits par les cellules du sang périphérique mononucléées (PBMC). Nous avons mis au point un système d’expression antigénique dans lequel nous contrôlons l’expression de MHC I, de HFE et d’un antigène pour lequel nous avons généré des lymphocytes T CD8+ spécifiques. Nos résultats démontrent que la forme sauvage de HFE (HFEWT), contrairement à sa forme mutée (HFEC282Y), inhibe la reconnaissance de complexes MHC I/peptide (pMHC). Nous avons également démontré que l'inhibition de la reconnaissance est maintenue, indépendamment des niveaux d'expression de MHC I à la surface, d'une compétition pour la β2-microglobuline, de la capacité de HFE d'interagir avec le récepteur de la transferrine, de l'origine de l'antigène ou de l'affinité de celui-ci. Par ailleurs, nous avons identifié les domaines α1-2 de HFEWT comme étant responsables de l'inhibition de la reconnaissance antigénique. Par contre, la reconnaissance de peptides chargés de manière externe sur les molécules du MHC I présentes à la surface n'a démontré aucune inhibition en présence de HFEWT, suggérant que HFEWT pourrait affecter la reconnaissance en interférant avec le processus d'apprêtement antigénique intracellulaire. À l’inverse, nous avons souhaité déterminer si les lymphocytes T activés pouvaient influencer les niveaux d'expression de HFE. En termes de régulation de l'expression de HFE, nous avons établi que HFE est exprimé dans les tissus sains chez l'humain et induit chez les lignées de cancers du colon, du sein, du poumon, du rein et du mélanome. Par ailleurs, en co-cultivant des lymphocytes T activés avec ces lignées tumorales, nous avons démontré que l'expression de HFE est fortement inhibée dans toutes ces lignées tumorales lorsqu'exposées à des lymphocytes T activés. Finalement, la modulation de l'expression de HFE est indépendante du contact cellulaire et semble médiée en partie par le GM-CSF, l'IFN-γ et le TNF. En somme, ces résultats suggèrent que les lymphocytes T de l'hôte modulent l'expression de HFE dans le microenvironnement inflammatoire, ce qui pourrait promouvoir la reconnaissance des antigènes présentés sur les molécules du MHC I présentées aux lymphocytes T CD8+ antigène-spécifiques. De plus, ces études soulèvent la possibilité d'un nouveau rôle physiologique de HFEWT dans la voie de présentation antigénique par MHC I, qui pourrait moduler l'immunogénicité des antigènes et la réponse immunitaire cellulaire chez l'hôte. / MHC class I antigen presentation is an ubiquitous process by which cells present endogenous proteins to CD8+ T lymphocytes during immune surveillance and response. Accordingly, classical MHC I molecules are up-regulated in response to inflammatory stimuli to favor immune recognition and pathogen clearance. HFE is a non-classical, MHC Ib molecule which acts as a negative regulator of iron absorption. HFE has been linked to the development of hereditary hemochromatosis (HH), an iron overload disease often associated to immune defects. Firstly, we studied the impact of HFE expression on MHC I antigen presentation, as a hypothesis for HH-associated immunological defects observed in HFEC282Y-mutated HH patients. Secondly, we evaluated whether, like its classical MHC I counterparts, HFE expression could be modulated in response to peripheral blood mononuclear cell (PBMC) inflammation. We developed an antigen presentation system in which we control MHC I expression, HFE expression, and expression of a model antigen for which we have generated antigen-specific CD8+ T lymphocytes. Our results demonstrate that wild-type HFE (HFEWT), but not C282Y-mutated HFE (HFEC282Y), inhibits recognition of MHC I antigens. We further demonstrate that inhibition of antigen recognition is maintained regardless of MHC I surface levels, β2-microglobulin competition, HFE ability to interact with transferrin receptor, antigen origin, or epitope affinity. We identified the α1-2 domains of HFEWT as being responsible for inhibiting antigen recognition. However, recognition of externally peptide-pulsed 293-A2 remained uninhibited in presence of HFEWT, indicating that HFE may affect T cell recognition by interfering with intracellular antigen processing. We also questioned whether activated T lymphocytes may influence HFE expression. We established that HFE is widely expressed in healthy human tissues and induced in colon cancer, breast cancer, lung cancer, kidney cancer and melanoma cell lines. Furthermore, HFE mRNA expression was drastically inhibited in all tumor cell lines when exposed to activated T lymphocytes. Down-regulation of HFE mRNA expression was independent of cell contact and appears to be partially mediated by GM-CSF, IFN-γ, and TNF. Overall, these data suggest that host T lymphocytes may alter HFE expression levels in the inflammatory microenvironment, which could, in turn, promote recognition of MHC I antigens presented to antigen-specific CD8+ T lymphocytes. Accordingly, this could suggest a new physiological role for HFEWT in the MHC I antigen presentation pathway, which could modulate antigen immunogenicity and the cellular immune response.

Mutações no gene HFE têm sido apontadas como um dos principais fatores para o desenvolvimento de sobrecarga de ferro, especialmente os SNPs (single nucleotide polymorphism) clássicos C282Y e H63D. A sobrecarga de ferro pode ser primária, atribuída diretamente a mutações do gene HFE (hemocromatose hereditária - HH) ou adquirida em decorrência de fatores genéticos e de comorbidades, particularmente, infecção pelo vírus da hepatite C (HCV) e carcinoma hepatocelular (CHC). Desequilíbrio de ligação entre os SNPs principais do gene HFE com alelos dos genes HLA-A e HLA-B podem contribuir com alterações da função das células do sistema imunológico. Neste trabalho, sequenciamos a região codificadora do gene HFE (éxon 2, 3, 4 e 5) de pacientes que apresentam ou não sobrecarga de ferro primária ou adquirida. Assim, estudamos 130 pacientes com hepatite C, 60 pacientes com CHC, 14 pacientes com HH e 100 indivíduos saudáveis. Foram encontrados sete SNPs no gene HFE no sentido 5\' para 3\': i) H63D C>G no éxon 2 (rs1799945); ii) IVS2(+4)T>C no íntron 2 (rs2071303); iii) íntron 3 C>G (rs807209); iv) C282Y G>A no éxon 4 (rs1800562); v) íntron 4 G>A (rs2794717); vi) IVS4(-44) T>C (rs1800708); vii) no íntron 5 a deleção G>del, ainda não foi descrita na literatura. Foram realizadas as reconstruções de haplótipos da região codificadora e os haplótipos estendidos englobando o gene HFE e dez outros loci (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, TNFa, TNFb, TNFc, TNFd e HLA-G-14pb). Também, normatizamos a nomenclatura do gene de acordo com as regras do The International ImMunoGeneTics Information System - IMGT (http://www.imgt.org/). Diversas ferramentas foram utilizadas para avaliar a associação entre os sítios polimórficos do gene HFE com a sobrecarga de ferro, incluindo testes de associações avaliando alelos, genótipos, desequilíbrio de ligação, haplótipos e diplótipos, testes de diversidades e neutralidade. Finalmente, comparamos os SNPs do gene HFE encontrados na população saudável do presente trabalho com as diversas populações mundiais, disponíveis no sítio 1000genomes (http://www.1000genomes.org/). Os resultados demonstraram que a nossa a população estava mais próxima das populações europeias e americanas, sendo parcialmente próxima das populações africanas e distante das populações asiáticas. O alelo C282Y G, contido no haplótipo da região codificadora HFE*01:03, conferiu susceptibilidade a HH na população brasileira testada, concordando com os achados observados em outras populações mundiais. O diplótipo HFE*01:02:01:01/HFE*01:01:01:05 conferiu susceptibilidade para o desenvolvimento de sobrecarga de ferro em pacientes com CHC causado pelo HCV. Detectamos forte desequilíbrio entre os alelos H63D G e IVS2(+4) C no éxon 2 do gene HFE, e concomitantemente, desequilíbrio desses alelos com alelo HLA-B*44, aparentemente, sem associação com sobrecarga de ferro, mas com aparente origem histórica. Finalmente, o teste de diversidade encontrou diferenças apenas na amostra de HH e o teste de neutralidade não encontrou pressões seletivas na população controle do presente trabalho. Concluindo, este é o primeiro trabalho, avaliando grande segmento da região codificadora do gene HFE em diversas amostras de pacientes apresentando ou não sobrecarga de ferro e em indivíduos controle. / Mutations at the HFE gene have been identified as a major factor for the development of iron overload, especially the classical single nucleotide polymorphism (SNP) C282Y and H63D. Primary iron overload can be directly attributed to mutations in the HFE gene (hereditary hemochromatosis - HH), whereas secondary overload may be acquired due to genetic factors and comorbidities, particularly infection with hepatitis C virus (HCV) and hepatocellular carcinoma (HCC). Linkage disequilibrium between major SNPs at the HFE gene with HLA-A and HLA-B alleles may contribute to alterations in the function of immune cells. We sequenced the coding region of the HFE gene (exon 2, 3, 4 and 5) of patients exhibiting primary or secondary iron overload. Thus, we studied 130 patients with hepatitis C, 60 patients with HCC, 14 patients with HH and 100 healthy individuals. We observed seven SNPs in the HFE gene in 5 \'to 3\' sequence: i) H63D C>G at exon 2 (rs1799945); ii) IVS2(+4)T>C at intron 2 (rs2071303); iii) intron 3 C>G (rs807209); iv) C282Y G>A at exon 4 (rs1800562); v) intron 4 G>A (rs2794717); vi) IVS4(-44) T>C (rs1800708); vii) at intron 5 we detected a yet undescribed G>deletion. We performed haplotype reconstruction of the coding region and extended haplotypes comprising the HFE gene and ten other loci (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, TNFa, TNFb, TNFc, TNFd and HLA-G14bp). In addition, we normatized the nomenclature of the HFE gene, according to the rules of the International ImMunoGeneTics Information System - IMGT (http://www.imgt.org/). Several tools were used to evaluate the association between HFE polymorphic sites with iron overload, including tests assessing associations of alleles, genotypes, linkage disequilibrium, haplotype and diplotypes, diversity and neutrality tests. Finally, we compare the SNPs at the HFE gene observed in the healthy population with those observed in diverse worldwide populations available at the 1000genomes site (http://www.1000genomes.org/) the results showed that our population was closer to American and European populations, partially close the populations of African and distant of Asian populations. The C282Y allele G, contained in the coding region HFE * 01:03 haplotype, conferred susceptibility to HH in the Brazilian population tested, agreeing with the findings observed in other worldwide populations. The HFE*01:02:01:01/HFE* 01:01:01:05 dyplotype conferred susceptibility to the development of iron overload in patients with HCC caused by HCV. A strong linkage disequilibrium was detected between the H63D G and IVS2 (+4) C alleles in exon 2 of the HFE gene, and concomitantly, a linkage between these alleles with HLA-B*44, apparently not associated with iron overload, but with apparent historical origin. Finally, the test of diversity revealed differences only in the HH sample and the neutrality test detected no selective pressures on the control population of this study. In conclusion, this is the first study evaluating a large segment of the coding region of the HFE gene in several samples of patients exhibiting or not iron overload and in control subjects.

Fundamentos: A porfiria cutânea tardia é a forma mais comum das porfirias e caracteriza-se pela diminuição da atividade da enzima uroporfirinogênio descarboxilase. Há vários relatos da associação das mutações do gene HFE da hemocromatose hereditária com porfiria cutânea tardia no mundo, mas até hoje apenas um estudo foi realizado no Brasil. Objetivo: Estudar a associação da porfiria cutânea tardia com as mutações C282Y e H63D do gene HFE da hemocromatose hereditária. Identificar a associação com etilismo, hepatite C, hepatite B e infecção pelo HIV e relacioná-los com a presença ou não das mutações do gene HFE e estudar retrospectivamente a resposta terapêutica à cloroquina. Métodos: Estudo ambispectivo para detectar as mutações C282Y e H63D em 60 pacientes com porfiria cutânea tardia no período de 2003 até 2012. O histórico familiar, etilismo, hepatite C, hepatite B e anti-HIV foram investigados. O estudo das mutações HFE foi realizado com PCR em tempo real. A resposta terapêutica foi avaliada utilizando a dosagem das porfirinas urinárias (urina de 24 horas), o perfil de ferro (ferro sérico, ferritina e saturação de transferrina) e as enzimas hepáticas antes e após a remissão bioquímica. Resultados: A frequência dos alelos das mutações foi significativamente mais elevada nos pacientes com PCT para C282Y (8,3% versus 1,77%, odds ratio 5,02, IC [95%] = [4,1%; 14,8%], p=0,0001) e H63D (27,5% versus 14,05, odds ratio 2,32, IC [95%] = [19,7%; 36,4%], p=0,0004) em relação à população grupo controle. A hepatite C estava presente em 41,7% dos pacientes e estava associada à ingestão de álcool em 71,7% dos casos. Conclusões: As mutações HFE e a expressão clínica da hemocromatose hereditária podem contribuir isoladamente para o desencadeamento da PCT, independente-mente da presença de outros fatores precipitantes; o que torna a pesquisa das mutações HFE um exame necessário nos pacientes com PCT. Nos pacientes homozigotos para C282Y e heterozigotos compostos (C282Y/H63D) a flebotomia é o tratamento de primeira escolha. A porfiria cutânea tardia pode ser um marcador cutâneo para a hemocromatose e o dermatologista pode auxiliar no seu diagnóstico e tratamento precoce. / Background: Porphyria cutanea tarda (PCT) is the most common form of porphyria and is characterized by the decreased activity of the uroporphyrinogen decarboxylase enzyme. Several reports associated HFE gene mutations of hereditary hemochromatosis with PCT worldwide, although up to date only one study has been conducted in Brazil. Objective: Study the association between porphyria cutanea tarda and C282Y and H63D mutations in the HFE gene of hereditary hemochromatosis. Identify the association with alcoholism, hepatitis C, hepatitis B and HIV infection and relate them with the presence or absence of the HFE gene mutations and study retrospectively the therapeutic response to chloroquine. Methods: Ambispective study in the period from 2003 to 2012 to detect the C282Y and H63D mutations in 60 patients with porphyria cutanea tarda. The family history, alcoholism, hepatitis C, hepatitis B and HIV were investigated. HFE mutations were held with real-time PCR. The therapeutic response was assessed using the urinary porphyrins (24h urine), the iron profile (serum iron, ferritin and transferrin saturation) and the liver enzymes, before and after biochemical remission. Results: The frequency of alleles of the mutations were significantly higher in patients with PCT for C282Y (8.3% vs. 1.77%, odds ratio 5.02, CI [95%] = [4.1%; 14.8%], p = 0.0001) and H63D (27.5% vs. 14.05, odds ratio 2.32, CI [95%] = [19.7% and 36.4%], p = 0.0004) in relation to group control population. Hepatitis C was found in 41.7% of the patients and was associated with the ingestion of alcohol in 71.7% of cases. Conclusions: The HFE mutations and clinical expression of hereditary hemochromatosis can contribute in an isolated manner to the outbreak of PCT, independently of the existence of other precipitating factors. This makes the search for HFE mutations necessary in patients with PCT. In patients who are homozygous for C282Y and compound heterozygotes (C282Y/H63D) phlebotomy is the treatment of first choice. Porphyria cutanea tarda can be a cutaneous marker for hemochromatosis and the dermatologist can help in its diagnosis and early treatment.

Resumo: A beta talassemia é um dos mais freqüentes distúrbios genéticos no mundo. Estima-se que 1,5% a 3% da população mundial seja portadora do traço talassêmico. Esses portadores geralmente são oligo ou assintomáticos e têm uma expectativa de vida semelhante à dos não portadores. Entretanto, níveis elevados de ferritina sérica têm sido observados em alguns estudos comparativos entre beta talassemia heterozigota e não portadores e, alguns indivíduos, que nunca foram transfundidos, apresentam sinais clínicos e laboratoriais de sobrecarga de ferro. A fisiopatologia dessa complicação continua em discussão. Vários pesquisadores têm sugerido um efeito modulador da mutação do gene da beta globina e mutações em genes codificadores de proteínas relacionadas ao metabolismo do ferro. Mutações no gene HFE são as mais freqüentemente associadas à hemocromatose hereditária. O objetivo do presente trabalho foi avaliar a freqüência das mutações C282Y e H63D no gene HFE em portadores de beta talassemia heterozigota e analisar sua influência no metabolismo do ferro. Foram estudados 162 portadores de beta talassemia heterozigota, residentes na cidade de São Carlos ou região, caucasóides e, acompanhados no serviço de Hematologia. O diagnóstico de traço talassêmico foi confirmado em todos por meio do eritrograma e da quantificação da Hb A2 e Hb fetal por HPLC. O metabolismo do ferro foi avaliado pelas dosagens de ferro sérico, capacidade total de ligação do ferro, ferritina e saturação da transferrina e, a análise molecular das mutações no gene HFE, pela técnica de PCR-RLFP. Foram realizadas análises de correlação linear de Pearson por idade e gênero entre hemoglobina... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Beta thalassemia is one of the most frequent genetic disorder in the world. It is estimated that 1.5% to 3% of the world population is a thalassemia carrier. These individuals are generally slightly symptomatic or asymptomatic and they have a life expectancy similar to those who are non-carriers. However, high levels of serum ferritin have been observed in some comparative studies between heterozygous for beta thalassemia and non-carriers, and some individuals that were never transfused, present clinic and laboratories signs of iron overload. The physiopathology of this disease continues in discussion. Several researchers have suggested a modulator effect from the mutation of the beta globin gene and mutations in genes related with the iron metabolism. Mutations of the gene HFE are the most frequently associated to the hereditary hemochromatosis. The aim of this study was evaluate the frequency of C282Y and H63D mutations in the HFE gene in beta thalassemia carriers, and analyze its influence in the iron metabolism. 162 beta thalassemia carriers, Caucasoid, residing in the city of Sao Carlos or region and accompanied in the Hematology service were studied. The diagnostic of thalassemia trait was confirmed in every one through a complete erythrogram and quantification of Hb A2 and Hb fetal by HPLC. The iron metabolism was evaluated by serum iron, total iron-binding capacity, serum ferritin and percent saturation of transferring. The molecular analysis of the mutations in the HFE gene was made by PCR-RLFP. There were made analysis of linear Pearson' correlation, by age and gender, among hemoglobin, Hb A2, VCM and among reticulocytes count and the values of saturation of transferrin and serum ferritin. / Orientador: Claudia Regina Bonini Domingos / Coorientador: Antonio José Manzato / Banca: Celso Carlos de Campos Guerra / Banca: Paula Rahal Liberatore / Mestre

Fundamentos: A porfiria cutânea tardia é a forma mais comum das porfirias e caracteriza-se pela diminuição da atividade da enzima uroporfirinogênio descarboxilase. Há vários relatos da associação das mutações do gene HFE da hemocromatose hereditária com porfiria cutânea tardia no mundo, mas até hoje apenas um estudo foi realizado no Brasil. Objetivo: Estudar a associação da porfiria cutânea tardia com as mutações C282Y e H63D do gene HFE da hemocromatose hereditária. Identificar a associação com etilismo, hepatite C, hepatite B e infecção pelo HIV e relacioná-los com a presença ou não das mutações do gene HFE e estudar retrospectivamente a resposta terapêutica à cloroquina. Métodos: Estudo ambispectivo para detectar as mutações C282Y e H63D em 60 pacientes com porfiria cutânea tardia no período de 2003 até 2012. O histórico familiar, etilismo, hepatite C, hepatite B e anti-HIV foram investigados. O estudo das mutações HFE foi realizado com PCR em tempo real. A resposta terapêutica foi avaliada utilizando a dosagem das porfirinas urinárias (urina de 24 horas), o perfil de ferro (ferro sérico, ferritina e saturação de transferrina) e as enzimas hepáticas antes e após a remissão bioquímica. Resultados: A frequência dos alelos das mutações foi significativamente mais elevada nos pacientes com PCT para C282Y (8,3% versus 1,77%, odds ratio 5,02, IC [95%] = [4,1%; 14,8%], p=0,0001) e H63D (27,5% versus 14,05, odds ratio 2,32, IC [95%] = [19,7%; 36,4%], p=0,0004) em relação à população grupo controle. A hepatite C estava presente em 41,7% dos pacientes e estava associada à ingestão de álcool em 71,7% dos casos. Conclusões: As mutações HFE e a expressão clínica da hemocromatose hereditária podem contribuir isoladamente para o desencadeamento da PCT, independente-mente da presença de outros fatores precipitantes; o que torna a pesquisa das mutações HFE um exame necessário nos pacientes com PCT. Nos pacientes homozigotos para C282Y e heterozigotos compostos (C282Y/H63D) a flebotomia é o tratamento de primeira escolha. A porfiria cutânea tardia pode ser um marcador cutâneo para a hemocromatose e o dermatologista pode auxiliar no seu diagnóstico e tratamento precoce. / Background: Porphyria cutanea tarda (PCT) is the most common form of porphyria and is characterized by the decreased activity of the uroporphyrinogen decarboxylase enzyme. Several reports associated HFE gene mutations of hereditary hemochromatosis with PCT worldwide, although up to date only one study has been conducted in Brazil. Objective: Study the association between porphyria cutanea tarda and C282Y and H63D mutations in the HFE gene of hereditary hemochromatosis. Identify the association with alcoholism, hepatitis C, hepatitis B and HIV infection and relate them with the presence or absence of the HFE gene mutations and study retrospectively the therapeutic response to chloroquine. Methods: Ambispective study in the period from 2003 to 2012 to detect the C282Y and H63D mutations in 60 patients with porphyria cutanea tarda. The family history, alcoholism, hepatitis C, hepatitis B and HIV were investigated. HFE mutations were held with real-time PCR. The therapeutic response was assessed using the urinary porphyrins (24h urine), the iron profile (serum iron, ferritin and transferrin saturation) and the liver enzymes, before and after biochemical remission. Results: The frequency of alleles of the mutations were significantly higher in patients with PCT for C282Y (8.3% vs. 1.77%, odds ratio 5.02, CI [95%] = [4.1%; 14.8%], p = 0.0001) and H63D (27.5% vs. 14.05, odds ratio 2.32, CI [95%] = [19.7% and 36.4%], p = 0.0004) in relation to group control population. Hepatitis C was found in 41.7% of the patients and was associated with the ingestion of alcohol in 71.7% of cases. Conclusions: The HFE mutations and clinical expression of hereditary hemochromatosis can contribute in an isolated manner to the outbreak of PCT, independently of the existence of other precipitating factors. This makes the search for HFE mutations necessary in patients with PCT. In patients who are homozygous for C282Y and compound heterozygotes (C282Y/H63D) phlebotomy is the treatment of first choice. Porphyria cutanea tarda can be a cutaneous marker for hemochromatosis and the dermatologist can help in its diagnosis and early treatment.

L’hémochromatose HFE est une maladie du métabolisme du fer liée au gène HFE dont la principale mutation est C282Y. L’objectif général de ce travail était d’étudier l’influence de facteurs génétiques et non génétiques sur l’expression phénotypique de patients atteints d’hémochromatose HFE. Cette étude prospective incluait les patients C282Y/C282Y etC282Y/H63D inclus en protocole de saignées entre janvier 2004 et décembre 2011 au centre de santé brestois de l’EFS-Bretagne. Dans un premier temps, nous avons étudié l’influence du génotype C282Y/H63D sur la survenue d’une surcharge en fer. Nous avons confirmé que le variant H63D doit être considéré comme un facteur de susceptibilité dont l’expression est liée à la présence de co-facteurs responsables d’une hyper ferritinémie. Ensuite, nous avons étudié le rôle des grossesses et de l’alimentation sur l’expression phénotypique du génotype C282Yhomozygote. Nous avons montré qu’il existe bien une différence d’expressivité clinique liée au sexe chez les patients C282Y/C282Y. Cependant, nos données n’ont pas confirmé l’effet protecteur typiquement attribué aux grossesses pour expliquer la plus lente accumulation de fer chez les femmes. Cette étude a également mis en évidence une association modérée entre la consommation d’aliments riches en fer et le degré de surcharge en fer des patients C282Yhomozygotes traités par phlébotomies. Ce travail contribue à mieux comprendre l’hétérogénéité phénotypique observée dans l’hémochromatose HFE. La finalité est de pouvoir repérer précocement les sujets les plus à risque de développer les surcharges en fer les plus sévères et par conséquent des complications cliniques. / HFE hemochromatosis is a disorder of iron metabolism related to the HFE gene whose mainmutation is C282Y. The overall aim of this study was to investigate the influence of genetic and non genetic factors on phenotypic expression of patients with HFE hemochromatosis. This prospective study included the C282Y/C282Y and C282Y/H63D patients enrolled in a phlebotomy program between 2004 and 2011 in a blood centre of western Brittany (Brest, France). First, weassessed the weight of the C282Y/H63D genotype in the occurrence of iron overload. We confirmed that H63D is a discrete genetic susceptibility factor whose expression is most visible in association with other co-factors responsible for hyper ferritinemia. Then we investigated the effect of pregnancies and iron-rich diet on phenotypic expressivity of the C282Y/C282Y genotype. We have shown that there is a difference in clinical expression related to gender in C282Y/C282Ypatients. However our findings did not confirm that pregnancies protect against iron accumulationin women. This study established a moderate link between dietary iron intake and the degree of iron overload in HFE hemochromatosis patients who come to medical attention. This work contributes to a better understanding of the phenotypic heterogeneity observed in HFE hemochromatosis. The purpose is to identify precociously subjects the most at risk of developing iron overload and therefore clinical complications.

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2012-07-20T20:46:00Z No. of bitstreams: 1 Joelma Figueiredo Menezes Estudo de polimorfismos....pdf: 11425878 bytes, checksum: 175372593b635c3bd50b3a10af52fc30 (MD5) / Made available in DSpace on 2012-07-20T20:46:00Z (GMT). No. of bitstreams: 1 Joelma Figueiredo Menezes Estudo de polimorfismos....pdf: 11425878 bytes, checksum: 175372593b635c3bd50b3a10af52fc30 (MD5) Previous issue date: 2010 / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil / Indivíduos com doença falciforme (DF) apresentam estresse oxidativo (EO) constante, que é decorrente da deficiência nos sistemas antioxidantes, caracterizados pela produção de espécies reativas do oxigênio (EROS) de origem multifatorial, principalmente geradas pelo processo hemolítico. Objetivo. Investigar polimorfismos relacionados ao estresse oxidativo nos genes HFE da hemocromatose hereditária (c.282C>Y, c.63H>D e c.65S>C); haptoglobina (HP), glutationa S-transferase (GST) (GSTT1 e GSTM1) e paraoxonase (PON1) (c.55L>M e c.192Q>R), associando-os aos dados hematológicos e bioquímicos, aos níveis séricos de vitamina C, paraoxonase 1 e receptor de transferrina e histórico clínico de pacientes com doença falciforme. Casuística e Métodos. A casuística foi composta por 153 indivíduos com DF (HbSS e HbSC) e 196 crianças saudáveis. O perfil de hemoglobinas foi determinado por HPLC. Os polimorfismos nos genes HFE, HP, GST, PON1, a presença da talassemia alfa 3,7Kb e 4,2Kb e dos haplótipos ligados ao grupo de genes da globina beta foram investigados por PCR e PCR-RFLP. A avaliação do perfil lipídico, hepático, função renal, inflamatório e metabolismo do ferro foram realizadas por técnicas espectrofotométricas. Os níveis séricos de vitamina C, receptor de transferrina solúvel e hemeoxigenase 1 total foram detectados por ELISA. Resultados. O estudo de polimorfismos no gene da GST demostrou que o genótipo Mu nulo foi o mais frequente em ambos os grupos estudados; a análise hematológica , nos indivíduos HbSS revelou diferença significante para os parâmetros de leucócitos (p=0,0452), de segmentados neutrófilos (p=0,0224) e o evento de STA (p=0,0423); nos indivíduos com DF foram encontradas diferenças para a uréia (p=0,0288) e ferritina (p=0,0316). No estudo do gene da Haptoglobina nos indivíduos com DF encontrou-se diferença significativa para contagem de reticulócitos (p=0,0167), ferritina sérica (p=0,0493); contagem de linfócitos típicos (p=0.0422) e LDH (p=0,0181); nos HbSS encontrou-se diferença para creatinina (p=0,0178) e ALT (p=0,0127). Para o gene HFE foi encontrada diferença significativa entre os alelos selvagem e mutante para o polimorfismo c.63H>D e contagem de plaquetas (p=0,0311) em indivíduos com DF; para o polimorfismo c.65S>C observou-se diferenças estatisticamente significativas para hemoglobina (p=0,0044) e hematócrito (p=0,0078). Nos HbSC para o polimorfismo c.63H>D observou-se entre os alelos selvagem e mutante diferenças significativas com o VCM (p=0,0032), HCM (p=0,0010) e linfócitos típicos (p=0,0242). Entre os indivíduos HbSS observou-se diferença significativa entre os alelos estudados e plaquetas (p=0,0078). Para a mutação c.65S>C observou-se diferenças significativas para os parâmetros de hemoglobina (p=0,0265) e hematócrito (p=0,0407) nos indivíduos HbSS e hemoglobina (p=0,0051) e hematócrito (p=0,0060) nos indivíduos HbSC. A análise do histórico clínico dos indivíduos com DF e o polimorfismo c.63H>D demonstrou diferença significativa para esplenomegalia, OR=3,38 (0,93 -12,22) e p=0,0402. Nos indivíduos HbSS foi encontrada diferença significativa entre os alelos c.63H>D e infecção, com OR=0,29 (0.07 -1,18) e p=0,0455. Para o gene PON1, a avaliação da atividade da PON1 nos indivíduos DF entre os alelos selvagem e mutante revelou diferença estatisticamente significativa, tendo o alelo selvagem maior atividade da PON1 que alelo mutante; para o polimorfismo PON1c.192Q>R observou-se entre os alelos selvagem e mutante diferenças significativas para as variáveis bioquímicas VLDL-C (p=0,0267) e triglicérides (p=0,0127). Nos HbSC verificou-se diferença estatística significativa para o PON1c.192Q>R e concentração de hemoglobina (p=0,0459), hematócrito (p=0,0225) e contagem de linfócitos típicos (p=0,0364). Para o PON1c.55L>M observou-se diferença significativa com a idade (p=0,0139), plaquetas (p=0,0109), creatinina (p=0,0329) e PCR (p=0,0141). Observou-se associação entre atividade da PON1 e esplenectomia (p=0,001); para hemeoxigenase e ferro sérico (p=0,023); e para vitamina C observamos correlação com colesterol HDL (p=0,037). Há correlação entre glutationa e vitamina C (p=0,035).Conclusões: Os polimorfismos estudados podem estar agindo sinergicamente com a hemoglobina variante S e assim influenciar na gravidade da doença, necessitando de outros estudos para validar estes resultados, uma vez que algumas destas investigações foram realizadas pela primeira vez neste grupo de indivíduos. / Patients with sickle cell disease (SCD) has continued oxidative stress (OS), which is resulting from ineffective antioxidant systems, characterized by production of reactive oxygen species (ROS) of multifactorial origin, mainly generated by the hemolytic process. Objective: To investigate polymorphism related to oxidative stress in hereditary hemochromatosis HFE gene (c.282C>Y, c.63H>D c.65S and D>C), haptoglobin (HP), glutathione S-transferase (GST) (GSTT1 and GSTM1) and paraoxonase (PON1) (c.55L>M and c.192Q>R), in association with the hematological and biochemical data, serum levels of vitamin C, paraoxonase 1, transferrin receptor and clinical manifestations of SCD patients. Methods. The sample included 153 individuals with SCD (HbSS and HbSC) and 196 healthy children. The profile of hemoglobin was determined by HPLC. The HFE gene polymorphisms, HP, GST, PON1, the presence of alpha thalassemia 3.7 Kb, 4.2 Kb and haplotypes of the beta gene cluster were investigated by PCR and PCR-RFLP. The lipid profile, liver, renal function, inflammation and iron metabolism was performed by spectrophotometric techniques. Serum levels of vitamin C, soluble transferrin receptor and total hemeoxigenase were investigated by ELISA. Results: The GST Mu null genotype was more frequent in both groups and both polymorphisms were in Hardy-Weinberg equilibrium. In the HbSS observed significant differences in the parameters of leukocytes (p = 0.0452) and segmented neutrophils (p = 0.0224) and event STA (p = 0.0423). Individuals with SCD had differences for urea (p = 0.0288) and ferritin (p = 0.0316). Evaluating the Haptoglobin gene in individuals with SCD found a significant difference for reticulocyte count (p = 0.0167), serum ferritin (p = 0.0493); typical lymphocyte count (p = 0.0422) and LDH (p = 0.0181); in the HbSS were found differences for creatinine (p = 0.0178) and ALT (p = 0.0127). For the HFE gene was found significant differences were observed between wild and mutant alleles for the polymorphism c.63H> D and platelet count (p = 0.0311) in individuals with SCD; for polymorphism c.65S> C were differences were statistically significant for hemoglobin (p = 0.0044) and hematocrit (p = 0.0078). In the HBSC observed significant differences in MCV (p = 0.0032), MCH (p= 0.0010) and typical lymphocytes (p = 0.0242). Among subjects HbSS were observed significant differences between alleles and platelets (p = 0.0078). For mutation c.65S> C showed significant differences in the parameters of hemoglobin (p=0.0265) and hematocrit (p=0.0407) in HbSS individuals, and hemoglobin (p=0.0051) and hematocrit (p=0.0060) in subjects HbSC. The analysis of the clinical history of individuals with SCD and polymorphism c.63H> D there was a significant difference for splenomegaly, OR = 3.38 (0.93 -12.22) and p = 0.0402. In HbSS individuals significant difference was found between alleles c.63H> D and infection, with OR = 0.29 (0.07 -1.18) p = 0.0455. For the PON1 gene, The activity assessment of PON1 in the individuals DF with wild and mutant genotypes showed statistically significant differences, the wild-type allele showed higher PON1 activity than the mutant allele; for the biochemical parameters to polymorphism PON1c.192Q> R and the values of VLDL-C (p = 0.0267) and triglycerides (p = 0.0127). In HbSC there was a statistically significant difference for PON1c.192Q> R and hemoglobin (p = 0.0459), hematocrit (p = 0.0225) and typical lymphocyte count (p = 0.0364). For PON1c.55L> M there was significant difference with age (p = 0.0139), platelets (p = 0.0109), creatinine (p = 0.0329) and CRP (p= 0.0141). There was an association between PON1 activity and splenectomy (p = 0.001) for hemeoxigenase and serum iron (p = 0.023), and vitamin C showed a correlation with HDL cholesterol (p = 0.037). There is a correlation between glutathione and vitamin C (p=0.035) Conclusions: The polymorphisms could be acting synergistically with this hemoglobin variant S, and influence the severity of disease, have been necessary further studies to validate these results, since some of these investigations were performed for the first time in this group of individuals.

Iron storage disease is a significant cause of liver disease and mortality in captive Egyptian fruit bats (Rousettus aegyptiacus). The nature of the susceptibility in this and other captive exotic species to iron storage disease is not clear. Hepcidin, a key iron regulatory hormone, is involved in the regulation of iron absorption in humans and other mammalian species and a deficiency in hepcidin has been associated with a number of genetic mutations resulting in hemochromatosis in humans. The objectives of this thesis were to identify whether there is a functional mutation in the hepcidin gene in the Egyptian fruit bat that may increase the susceptibility of this species to iron storage disease, and whether there is a functional deficiency in hepcidin gene expression in the Egyptian fruit bat in response to iron challenge. We compared the coding region of the hepcidin gene amongst several species of bats and investigated hepcidin response to intramuscular injection of iron dextran amongst three species of bats with variable susceptibility to iron storage disease; the Egyptian fruit bat, the straw-colored fruit bat (Eidolon helvum), and the common vampire bat (Desmodus rotundus). While a number of genetic differences were identified amongst species, a functional mutation that could result in decreased hepcidin activity was not identified in the Egyptian fruit bat. Bats exhibited marked variation in hepcidin gene expression, with the highest level of hepcidin response to iron challenge in the common vampire bat. While the Egyptian fruit bat exhibited significant hepcidin response to iron challenge, the magnitude of response was lower than that in the common vampire bat and lower than expected based on findings in healthy humans. The straw-colored fruit bat did not exhibit any hepcidin response despite a significant increase in iron stores, which suggests this species may have evolved an alternate mechanism for coping with excessive iron or may be more susceptible to iron overload than previously recognized. / Toronto Zoo Scholarship Fund